

Government Medical Store Depot New Delhi
Medical Stores Organization
Directorate General of Health Services
Ministry of Health and Family welfare
C-4, Qutub Institutional Area, New Delhi-110016

Minutes of the Pre-Bid Meeting

Tender No.: PS/2/RE/Gr B/249/2026-2027/01
Tender ID: 2026_DGHS_904224

Subject: Procurement of 249 Group-B Generic Drugs

The Pre-Bid Meeting in respect of the above-mentioned tender was held on 10.04.2026 at 11:00 AM in the Conference Room, GMSD New Delhi under the Chairpersonship of Dr. Anju Nanda, DDG (Stores), MSO.

The meeting was attended by officers/officials of MSO/GMSD and representatives of prospective bidders. The following departmental officers were present during the meeting:

1. Dr. G.S. Jhankar, CMO (NFSG), In-charge GMSD, New Delhi
2. Dr. Zeasaly S K Marak AD, MSD (CGHS), Gole Market New Delhi
3. Sh. Girdhari Lal, Sr. AO, GMSD New Delhi
4. Sh. Chohan Tudu, ADM, GMSD New Delhi
5. Smt. Shalini, PCC, GMSD New Delhi
6. Sh. Aniket Tangri, PCC, GMSD New Delhi

At the outset, the Chairperson welcomed all participants and informed that all queries received through email and letters, as well as those raised during the meeting, would be duly examined. It was further informed that the clarifications issued during the pre-bid meeting shall form an integral part of the tender document.

All queries received were examined and consolidated under thematic areas. The decisions taken are in accordance with tender conditions, GFR 2017, and principles of transparency, fairness, and competition.

Clarifications & Decisions

All queries were examined and consolidated under thematic areas. No modification in eligibility criteria, warehouse requirements, delivery period, regulatory compliance, and technical specifications was considered necessary unless explicitly clarified. Certain operational relaxations and documentation clarifications have been allowed as detailed in the MOM.

A summary of bidder-wise queries and their disposition is placed at Annexure-I. Detailed clarifications have been issued in thematic form to ensure uniformity and transparency.

With regard to **eligibility criteria, including turnover requirements, mandatory warehouse conditions under Annexure-K, and requests for supply through distributors or C&F agents**, it was decided that no modification is warranted. The existing provisions have been framed to ensure reliable supply across all GMSDs, compliance with prescribed storage and distribution norms, and timely execution of supply orders. Accordingly, **the requirement for maintaining warehouses in each GMSD jurisdiction shall remain unchanged unless specified further and requests for centralized or zonal warehousing models arrangements are not admissible.**

On the issue of **delivery period**, several bidders requested extension from 45 days to 60 days citing API shortages and logistical challenges. After due consideration, **the request was not accepted.** The delivery period as stipulated in the tender, is retained since it is aligned with operational requirements of GMSD/CGHS and is critical to ensuring uninterrupted availability of medicines.

Regarding **regulatory compliance, particularly in respect of Fixed Dose Combinations (FDCs)**, it was clarified that CDSCO/DCGI approval is mandatory wherever applicable. **Bidders shall submit valid CDSCO/DCGI approval certificates for FDC drugs at the time of bid submission, unless otherwise specified. No relaxation in regulatory requirements is permissible.**

With respect to **technical specifications**, including composition, strength, nomenclature, and pharmacopoeial standards, requests for modifications were examined but not accepted. It is reiterated that the specifications provided in the **Schedule of Requirement (SOR) are to be strictly adhered to, and no deviation in composition or strength is permitted until specified further.**

In relation to **dosage forms**, it is clarified that **capsule and tablet forms, injections and vials shall be treated at par**, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. **Value-added formulations** such as SR/CR/ER/XR/PR/MR etc are **acceptable** and will be treated at par for evaluation purposes.

On the matter of **packing and pack size**, it is clarified that **larger pack sizes may be accepted** subject to rate equivalence with the pack size specified in the SOR. **Alternative pack sizes**, such as strip of 15 tablets or capsules, **may be considered** provided all other tender conditions are complied with. **Rates shall be normalized appropriately on a per unit basis wherever required.**

Requests for **relaxation in shelf life** conditions, including acceptance of products with **lower shelf life** such as 18 months, will be **accepted until approved/specified by Drug Controller.** The shelf-life criteria prescribed in the tender document shall remain unchanged and must be strictly complied with.


With regard to **documentation requirements**, it is clarified that Annual Turnover Certificates, Balance Sheets, and Profit & Loss Statements bearing valid UDIN shall be **accepted even if the tender ID is not mentioned.** Bidders are required to **submit samples of primary packing except for injectables, prior to tender opening** as per tender conditions. **Third-party manufacturing or marketing arrangements shall not be admissible** where specifically restricted under the tender provisions.

A specific operational **relaxation was considered** in respect of supply to **Karnal GMSD from Zirakhpur and Mohali warehouse.** Considering geographical proximity (satellite city) and operational feasibility, such supply shall be permitted. However, this relaxation is strictly case-specific and shall not be construed as a general waiver of the warehouse requirements prescribed under the tender.

Further, with regard to warehouse requirements, it is clarified that **warehouses located within the National Capital Region (NCR) of Delhi shall be considered** as meeting the requirement for GMSD New Delhi. Additionally, warehouses situated in locations falling within the common operational jurisdiction or geographical proximity of **Delhi NCR and Karnal shall be considered** valid for servicing both GMSD New Delhi and GMSD Karnal, subject to operational feasibility.

It is further informed that necessary corrections in item descriptions, including those identified during the pre-bid stage, shall be issued through a corrigendum on the CPP Portal.

Additional clarifications include that **larger pack sizes** may be accepted subject to rate parity, and **unit-based pricing** shall be **applicable** wherever relevant. **Existing Rate Contract holders may continue to supply medicines till the validity of their contracts.** The **roadmap for procurement cycle** has already been communicated and is available on the DVDMS portal.



With regard to registration of manufacturing units with MSO, it is clarified that bidders may submit provisional documents such as proof of application, including bids or acknowledgements, at the time of bid submission. However, submission of the final valid registration certificate shall be mandatory by the stage of technical evaluation, i.e., on or before 26th May 2026, failing which the bid shall be treated as non-responsive and liable for rejection.

With respect to submission of Non-Conviction Certificate, it is clarified that the certificate should preferably be general in nature and not organization-specific or tender-specific. In case the certificate is organization-specific or tender-specific, it shall be considered valid only if it pertains specifically to this tender. Certificates issued for any other organization or bearing reference to any other tender shall not be considered acceptable. In cases where the validity period of the certificate is not explicitly mentioned, the same shall be treated as valid for a period of six months from the date of issue.

Regarding API traceability and Batch Manufacturing Record (BMR), it is clarified that relaxation in submission of BMR shall be applicable only in respect of imported products and Biological products where items are accepted based on Inhouse Test Report as per the provisions of the tender document.

With reference to the Bill of Quantities (BOQ), it is clarified that the rate unit indicated as "1" shall be construed as the unit rate for the respective item. Accordingly, bidders are required to quote rates on a per unit basis, such as per tablet, capsule, bottle, tube, respule, inhaler, rotacap, respicap, kit, ampoule, vial, sachet, pre-filled syringe (PFS), oral dispersible strip (ODS), flexipen, cartridge, or any other applicable unit as per the item description.

With regard to submission of the tender document, it is clarified that in view of the large file size, bidders may submit the complete tender document, duly signed and stamped, along with the Integrity Pact as per the prescribed requirements. However, at the time of submission of bids, bidders shall mandatorily submit the first two pages and the last two pages of the tender document, duly signed and stamped by authorized signatory, as a token of acceptance and for reference purposes.

It is clarified that provisions regarding Global Tender Enquiry (GTE) exemption shall be governed strictly as per the applicable provisions of GFR 2017 and the Public Procurement (Make in India) policy, as amended from time to time. No separate deviation is envisaged under this tender.

Annexure-I

Summary of Bidder-wise Queries and their Disposition

Name of the Firm	Queries and request for clarification/amendments raised in the Pre-Bid meeting by the prospective Bidder/s to the Committee	Clarification
1. M/s Precise Biopharma Pvt. Ltd.	<p>(i) Establishing ware house at all GMSD Location is not economically justified for either bidder or the procurement system especially when distributor-based supply is already operational. We humbly suggest that GMSD may permit direct supply from manufacturers.</p> <p>(ii) Please note that, state drug controller can only issue drug license of Fix dose combination (FDC) subject to provide by DCGI, Hence request to kindly list of FDC drug approved by DCGI which is available on their official portal and in the public portal.</p> <p>(iii) Due to America -Iran War situation acute shortage of API and disrupted whole supply chain however we request to kindly increased delivery period 60 days instead of 45 days</p>	<p>It was clarified that:- It is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:- CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission</p> <p>Not admissible</p>
2. Precise Chemi Pharma Pvt. Ltd.	<p>(iv) Establishing ware house at all GMSD Location is not economically justified for either bidder or the procurement system especially when distributor-based supply is already operational. We humbly suggest that GMSD may permit direct supply from manufacturers.</p> <p>(v) Please note that, state drug controller can only issue drug license of Fix dose combination (FDC) subject to provide by DCGI, Hence request to kindly list of FDC drug approved by DCGI which is available on their official portal and in the public portal.</p> <p>Due to America -Iran War situation acute shortage of API and disrupted whole supply chain however we request to kindly increased delivery period 60 days instead of 45 days</p>	<p>It was clarified that:-It is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:- CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission</p> <p>Not admissible</p>
3. M/s Theon Pharmaceuticals Limited	<p>(i) Tender condition requiring "The Bidder must have at least one warehouse in the state of each GMSD" along with the requirement of submitting Annexure-K may kindly be reconsidered and removed.</p> <p>(ii) Requested for amendment in Nomenclature of item VMS No G170239 From Pre & Probiotic Tab/Cap-Each Tab/Cap.to contain: Streptococcus Faecalis T - 110 60 Million, Clostridium Butyricum TO-A 4 Million, Bacillus Mesentericus TO-A 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes) To Pre & Probiotic Tab/Cap-Each Tab/Cap.to contain: StreptococcusFaecalis 60Million, Clostridium Butyricum 4Million, Bacillus Mesentericus 2Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes). The bidder requested that words T - 110 & TO-A may be removed from the composition as these words are prefixed to APIs whereas this products generic composition is available without prefixed words in the market.</p>	<p>It was clarified that:-It is part of our approved tender document and cannot be changed.</p> <p>It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.</p>
4.M/s Mascot Health Series Pvt. Ltd.	<p>(i) Request for revising the requirement from State wise warehouse to a four zone based system</p> <p>(ii) Request to increase delivery period 60 days instead of 45 days.</p> <p>(iii) Kindly provide detailed guidelines on documentation requirements for FDC approval to ensure compliance.</p>	<p>It was clarified that:-This is a part of our approved tender document and cannot be changed.</p> <p>It is clarified that :-The delivery period of 45 days is as per the approved tender conditions and cannot be increased.</p> <p>It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission</p>

<p>Biodeal Pharmaceuticals Limited.</p>	<p>(i) Request for revising the requirement from State wise warehouse to a four zone based system</p> <p>(ii) Request to increase delivery period 60 days instead of 45 days.</p> <p>(iii) With respect to DCGI approval for Fixed Dose Combinations (FDC), clarity is required regarding the specific documentation to be submitted.</p> <p>Request: Kindly provide detailed guidelines on documentation requirements for FDC approval to ensure compliance.</p>	<p>It was clarified that:-This is a part of our approved tender document and cannot be changed.</p> <p>It is clarified that:-The delivery period of 45 days is as per the approved tender conditions and cannot be increased.</p> <p>It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission</p>
<p>6. M/s Sun Pharma Laboratories Limited.</p>	<p>We respectfully request a relaxation of the condition requiring a branch office in Karnal. We are fully capable of servicing the contract from our Zirakhpur branch, which is operationally equivalent and located within close proximity to Karnal. We are confident that this relaxation will not compromise the timely and efficient execution of the tender obligations.</p> <p>We have established, fully functional branches in Chennai, Guwahati, Hyderabad, Kolkata, Mumbai and Delhi/NCR. The Zirakhpur branch efficiently serves the Karnal region as part of our North India operations.</p>	<p>It is clarified that :-Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.</p>
<p>7. M/s SunPharmaceutical Industries Limited</p>	<p>We respectfully request a relaxation of the condition requiring a branch office in Karnal. We are fully capable of servicing the contract from our Zirakhpur branch, which is operationally equivalent and located within close proximity to Karnal. We are confident that this relaxation will not compromise the timely and efficient execution of the tender obligations.</p> <p>We have established, fully functional branches in Chennai, Guwahati, Hyderabad, Kolkata, Mumbai and Delhi/NCR. The Zirakhpur branch efficiently serves the Karnal region as part of our North India operations.</p>	<p>It is clarified that:- Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.</p>
<p>8. M/s Bayer Pharmaceuticals Pvt. Ltd.</p>	<p>We respectfully request a relaxation of the condition requiring a branch office in Karnal. We are fully capable of servicing the contract from our Zirakhpur branch, which is operationally equivalent and located within close proximity to Karnal. We are confident that this relaxation will not compromise the timely and efficient execution of the tender obligations.</p> <p>We have established, fully functional branches in Chennai, Guwahati, Hyderabad, Kolkata, Mumbai and Delhi/NCR. The Zirakhpur branch efficiently serves the Karnal region as part of our North India operations.</p>	<p>It is clarified that :-Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.</p>
<p>9. M/s Raptakos, Brett & Co. Ltd</p>	<p>We respectfully request a relaxation of the condition requiring a branch office in Karnal. We are fully capable of servicing the contract from our Zirakhpur branch, which is operationally equivalent and located within close proximity to Karnal. We are confident that this relaxation will not compromise the timely and efficient execution of the tender obligations.</p> <p>We have established, fully functional branches in Chennai, Guwahati, Hyderabad, Kolkata, Mumbai and Delhi/NCR. The Zirakhpur branch efficiently serves the Karnal region as part of our North India operations..</p>	<p>It is clarified that :-Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.</p>
<p>10. M/s Tablet India Limited</p>	<p>1. We sincerely request your kind consideration to grant us exemption from the requirement of having a warehouse in GMSD Guwahati, Karnal and Hyderabad.</p> <p>2. Proposed Request: 1. Kindly remove the following columns from Annexure-J: * Source of API * Address of Source of API 2. Kindly remove the requirement of submitting detailed Batch Manufacturing Records as part of this undertaking.</p> <p>3. Proposed Amended Clause: The Bidder must have a minimum of four (4) functional warehouses @ Metropolitan cities (Chennai, Mumbai, Kolkata and New Delhi) out of the seven (7) GMSD jurisdictional states, with each warehouse located within the respective jurisdictional states of those four (4) GMSDs. Along with: i. Drug license of warehouse location ii. GST registration certification iii. Last 3 months GST Return of warehouse</p>	<p>It is clarified that :-Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.</p> <p>In case of Guwahati and Kolkata we may not exempt.</p> <p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p> <p>It was clarified that :-it is part of our approved tender document and cannot be changed.</p>

4. we would like to request you to amend (which are bold and underlined) for (Tender VMS. No: G170021, G170232, G170236, G170239, G270037 & G270194): So as to enabling us to participate in the tender.

Tender Sl. No	Composition as per tender condition	Amendment Required
87	Tender VMS. No. G170021	Bacillus mesentericus and Lactobacillus Sporogenes Capsules
	Bacillus mesentericus TO-A JPC 1 Million+ Lactobacillus sporogenes 50 Million Tab Pack: Strip of 10 Tablet	Each capsule contains: Bacillus Mesentericus TO-A JPC 1 Million Lactobacillus Sporogenes 50 Million Pack: Strip of 10 Capsules
112	Tender VMS.No.G170232	Polyethylene Glycol 3350 and Electrolytes for Oral Solution USP (137.15gm)
	Polyethylene glycol 4000 IP 118g Potassium chloride IP 1.484g Sodium bicarbonate IP 3.370g Sodium chloride IP 2.93g Anhydrous Sodium Sulfate BP 11.360g	Each pack (137.15g) contains: Polyethylene Glycol 3350 USP 118.0gm Sodium Chloride IP 2.93gm Potassium Chloride IP 1.484gm Sodium Bicarbonate IP 3.370gm Anhydrous Sodium Sulfate BP 11.360gm
113	Tender VMS. No. G170236	Pre and Probiotic Granules for Oral Suspension 50ml
	Pre & Probiotic Dry Syp - Each 5ml to contains: Streptococcus faecalis T-110 30 million Clostridium butyricum TO-A 2million Bacillus mesentericus TOA 1 million Lactic acid bacillus (Lactobacillus sporogenes) 50 million Excipients q.s.	Each 5ml of the reconstituted suspension contains: Streptococcus faecalis T-110 JPC 30 Million Clostridium butyricum TO-A 2 Million Bacillus mesentericus TO-A JPC 1 Million Lactic acid bacillus (Lactobacillus Sporogenes) 50 Million Excipients q.s.
114	Tender VMS.No. G170239	Pre and Probiotic Capsules - DS
	Pre & Probiotic Tab/Cap Each Tab/Cap.to contain: Streptococcus Faecalis T - 110 60 Million, Clostridium Butyricum TO-A 4 Million, Bacillus Mesentericus TO-A 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes) Pack: Strip of 10 Tablet	Each Capsule contains: Streptococcus Faecalis T-110 JPC 60 Million Clostridium Butyricum TO-A 4 Million Bacillus Mesentericus TOA JPC 2 Million Lactic Acid Bacillus (Lactobacillus Sporogenes) 100 Million Pack: Strip of 10 Capsules

It was clarified that:- both the Oral Dosage form of the Generic drug i.e. Capsule / Tablet is acceptable and will be treated at par, until unless explicitly not allowed by Pharmacopeia /Rules

It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.

It was clarified that:- the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.

It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.

222	Tender VMS.No. G270037	Streptococcus faecalis, Clostridium butyricum, Bacillus mesentericus, Lactobacillus sporogenes, Saccharomyces Boulardii Capsules
	Bacillus Mesentericus 1Million Spores+	Each Capsule Contains:
	Clostridium Butyricum 2Million Spores+	Streptococcus faecalis T-110 JPC 30 Million
	Lactobacillus Sporogenes 50Million Spores+	Clostridium butyricum TO-A 2 Million
	Saccharomyces Boulardii 50Million Spores+	Bacillus Mesentericus TO-A JPC 1 Million
	Streptococcus Thermophilus 30Million Spores Cap	Lactic Acid Bacillus (Lactobacillus Sporogenes) 50 Million
		Saccharomyces Boulardii 50 Million
241	Tender VMS.No. G270194	Amino Acids and Vitamins Capsules
	L-Leucine 18.3 mg+ L-Isoleucine 5.9 mg.+ L-Lysine Hydrochloride 25.0 mg+ L-Phenylalanine 5.0 mg+ L-Valine 6.7 mg+ LTryptophan 5.0 mg+ DL-Methionine 18.4 mg+ 5-Hydroxy Anthranilic Acid Hydrochloride 0.2 mg+ Vit. A concentrate 2500 IU+ Vit D3 200 IU+ Thiamine Mononitrate 5.0 mg.+ VitB2 3.0 mg+ Nicotinamide 25 mg+ Vit. B6 1.5 mg.+ Folic Acid 0.75 mg+ Calcium Pantothenate IP 5.0mg.+ Vit. B12 2.5 mcg.+ Vit. C 40.0 mg+ Vit. E acetate 7.5 IU+ LThreonine 4.2 mg. Tab/Cap Shelf Life: 24 Months	Each Capsule contains: L-Leucine USP 18.3 mg L-Isoleucine USP 5.9mg L-Lysine Hydrochloride IP 25.0 mg L-Phenylalanine IP 5.0 mg L-Threonine IP 4.2 mg L-Valine IP 6.7 mg L-Tryptophan IP 5.0 mg DL-Methionine BP 18.4 mg 5-Hydroxy Anthranilic Acid Hydrochloride 0.2 mg Vitamin A (as Vitamin A Concentrate Powder Form) IP 2500 IU Cholecalciferol IP 200 IU Thiamine Mononitrate IP 5.0 mg Riboflavin IP 3.0 mg Nicotinamide IP 25.0 mg Pyridoxine Hydrochloride IP 1.5 mg Folic Acid IP 0.75 mg Calcium Pantothenate IP 5.0 mg Cyanocobalamin IP 2.5 mcg Ascorbic Acid IP 40.0mg Tocopheryl Acetate IP 7.5 IU Shelf Life: 18 Months: Special Note: We have supplying this product over 40 years with Shelf Life of 18months based on stability study conducted by our plant. To increase shelf life to 24 months we have conduct stability study which will take a year and above. Hence, our kind request is to allow us to participate with our current shelf life of 18 months.

It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.

It was clarified that :-it is part of our approved tender document and cannot be changed

Astonea	<p>1. Kindly reconsider and reduce the turnover criteria</p> <p>2. Withdraw warehouse clause</p> <p>3. Restore the delivery period to 60 days, as per earlier practice</p>	<p>It was clarified that :-it is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p>										
12. M/s DwD Pharma	<p>We have a state-of-the-art WHO-GMP accredited manufacturing facility located in Gujarat.</p> <p>Our organization has a strong pan-India presence, with a field force of over 1,500 personnel covering doctors across the country. We hold a leadership position in several therapeutic segments. Our robust distribution network is supported by 20 C&F agents and more than 3,000 stockists nationwide.</p> <p>DWD Pharmaceuticals Ltd. has been an approved and registered manufacturer with M.S.O. since 02/06/2021. We currently operate through our own C&F agencies in five of the seven G.M.S.D. locations, namely Kolkata, Guwahati, Mumbai, Hyderabad, and Chennai. Additionally, we have a C&F agency in Jaipur, through which we can efficiently cater to GMSD Delhi and Karnal.</p> <p>We are keen to appoint an All India Distributor for GMSD supplies, who will further ensure seamless distribution to all GMSD locations. In view of our strong infrastructure and extensive distribution capabilities, we do not foresee any challenges in executing supplies against GMSD purchase orders.</p> <p>In light of the above, we kindly request your good office to consider granting a waiver for Annexure K and the related qualification criteria.</p> <p>We look forward to your favorable consideration.</p>	<p>It was clarified that :-it is part of our approved tender document and cannot be changed.</p>										
13. M/s HAB Pharmaceuticals	<p>The bidder must have at least one warehouse in the state of each GMSD, 1 supported by: Drug License of warehouse location GST Registration Certificate Last three months' GST Returns</p> <p>DCGI permission is to be submitted for all Fixed Dose Combinations (FDCs) and new drugs quoted.</p> <p>Delivery Period The time for and the date of delivery of stores stipulated in the supply order shall be deemed to be the essence of the contract and delivery must be completed within stipulated Date of Delivery which is normally 45days unless specified otherwise.</p>	<p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission</p> <p>It is clarified that:-the delivery period of 45 days is as per the approved tender conditions and cannot be increased.</p>										
14. M/s IPCA Laboratories	<table border="1" data-bbox="295 1299 1173 1422"> <thead> <tr> <th>Sl. No</th> <th>VMS No</th> <th>Item Description (Nomenclature + Strength + Specification)</th> <th>Packing / Pack Size / Dosage form required by you</th> <th>Our Dosage For</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>G170078</td> <td>Domperidone 30mg + Rabeprazole 20mg Tab</td> <td>Tablet</td> <td>Capsule</td> </tr> </tbody> </table>	Sl. No	VMS No	Item Description (Nomenclature + Strength + Specification)	Packing / Pack Size / Dosage form required by you	Our Dosage For	1	G170078	Domperidone 30mg + Rabeprazole 20mg Tab	Tablet	Capsule	<p>It was clarified that:- both the Oral Dosage form of the Generic drug i.e. Capsule / Tablet is acceptable and will be treated at par, until unless explicitly not allowed by Pharmacopeia /Rules.</p>
Sl. No	VMS No	Item Description (Nomenclature + Strength + Specification)	Packing / Pack Size / Dosage form required by you	Our Dosage For								
1	G170078	Domperidone 30mg + Rabeprazole 20mg Tab	Tablet	Capsule								
15. M/s Logos Pharma	<p>1. Mandatory Warehouses in Seven States Requiring manufacturers to maintain warehouses in all seven states significantly increases operational and financial burden. Economic Impact: GMSD typically places orders only 3-4 times per year. Maintaining seven warehouses is cost-prohibitive and could unnecessarily inflate bid prices. Regulatory Context: Under the current GST regime based on the "One Nation, One Tax" principle, interstate supplies do not necessitate maintaining multiple state-wise warehouses or separate registrations.</p> <p>2. Reduced Delivery Timeline The revised 45-day delivery period is challenging, as production begins only after a confirmed order. The complete cycle-including API procurement, production, testing, and quality control demands adequate time. Additionally, nationwide logistics require careful planning to maintain product integrity.</p>	<p>It was clarified that :-it is part of our approved tender document and cannot be changed.</p> <p>It is clarified that :-the delivery period of 45 days is as per the approved tender conditions and cannot be increased.</p>										
16. M/s Preet Remedies	<p>1. Turnover Clause: you have increased turnover from 50 Crore to 100 crore for Group B and 100 crores to 200 crores for group A. Due to above change, we shall not be able to participate in group A, though our firm is recently registered with MSO till 20.07.2027.</p> <p>2. You have also incorporated another restrictive clause stating that manufacturer should have warehouses in all these 7 states Where GNMSD are located. This class will not only restrict us but to several MSME firms/companies. On one hand, the Central government is promoting MSME by various supports, the other, you have introduced restrictive clause. As per Current practice, GMSD will Procure maximum 3 to 4 times in a year Therefore, Introduction of this clause will only increase the cost as such Witt be used for very limited period. Further, post GST era, there is no need to have multiple houses and GST numbers.</p> <p>3. You have also reduced the delivery period from 60 days to 45 days. It is pertinent to mention here that we start manufacturing for your orders after receiving confirm orders from your side. This includes procurement and testing of API, Production, And testing of finish goods before dispatches to GMSD. There are certain products which require sterile test for API And also finish product. It may go up to 42 days, Also, transportation to various GMSDs in the country.</p> <p>In view of the above, you are requested to kindly reduce the turnover, withdraw the Newly introduced warehouses clause and restore the 60 days delivery period</p>	<p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p> <p>It was clarified that:- it is part of our approved tender document and cannot be changed.</p> <p>It is clarified that:- the delivery period of 45 days is as per the approved tender conditions and cannot be increased.</p>										

1. We humbly request that GMSD may consider permitting direct supply from manufacturers, as this would enhance operational efficiency, improve supply chain control, and ensure timely and reliable delivery of goods.

2. It is submitted that State Drug Controllers issue manufacturing licenses for Fixed Dose Combinations (FDCs) only after due approval from DCGI. Therefore, we request that the list of DCGI-approved FDCs available on the official/public portal may be accepted as valid compliance. This approach is also being followed in ESIC tenders (relevant clause enclosed for reference).

3. Due to the ongoing geopolitical situation, particularly the America-Iran conflict, there is an acute shortage of APIs and disruption in the global supply chain. In view of this, we request that the delivery period may kindly be extended from 45 days to 60 days to ensure uninterrupted and quality supply.

It was clarified that:- it is part of our approved tender document and cannot be changed.
It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission

It is clarified that:- the delivery period of 45 days is as per the approved tender conditions and cannot be increased

18. M/s Synokem Pharma

1. Relaxation in Annexure-K warehouse requirement to allow supply through authorized distributors

2. Permission to participate with valid State Licensing Authority approvals along with DCGI-approved products

3. Extension of delivery period from 45 days to 60 days

4. Necessary corrections in product specifications as per the attached details with respective VMS numbers

Sl No.	Item Description (Nomenclature+ Strength + Specification)	Amendment Request	VMS Number
1	Itopride 150mg + Pantoprazole 40mg Cap	Pantoprazole Sodium 40 mg + Itopride HCL (SR Pellets) 150 mg	G170120
2	Levosulpiride 75mg + Rabeprazole 20mg Tab	Rabeprazole Sodium IP 20 mg + Levosulpiride 75 mg (as sustained release)	G170144

It was clarified that:- it is part of our approved tender document and cannot be changed.

It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission

It is clarified that :-the delivery period of 45 days is as per the approved tender conditions and cannot be increased

It was clarified that:-Any value addition like SR/ CR/ ER XR/ PR/MR OD etc. In formulation of the generic drug is acceptable and will treated at par

19. M/s Tasmed

Request In light of the above, we earnestly request you to:

- Revert the Turnover Clause to the previous limits.**
- Withdraw the Mandatory Warehouse Clause to encourage broader participation.**
- Restore the 60-day Delivery Period to ensure the supply of quality-tested pharmaceutical products.**

It was clarified that:- it is part of our approved tender document and cannot be changed.

It was clarified that :-it is part of our approved tender document and cannot be changed

It is clarified that:- the delivery period of 45 days is as per the approved tender conditions and cannot be increased

20. M/s Windlas Biotec

We sincerely request you to kindly consider our suggestion and amend Annexure-K accordingly in four zone.

It was clarified that:- it is part of our approved tender document and cannot be changed

21. M/s Zim laboratories

1. We request that the below CA-certified documents:
 1. Annual Turnover Certificate,
 2. Balance Sheet and Profit & Loss Statement,
 which have already been issued with a valid UDIN, may be considered acceptable even if the tender ID is not mentioned.

Requiring fresh certificates with the tender ID would lead to redundant certification work, additional cost and time, without adding any further authenticity beyond the UDIN, which already ensures the authenticity and traceability of the certificates.

In view of the above, we kindly request you to consider the aforesaid certificates bearing valid UDIN without insisting on mention of the tender ID.

2. Schedule of Requirements.
 VMS No. G160029
 Item Description & Strength:
 Dutasteride + Tamsulosin 0.5mg+ 0.4mg
 Packing/Dosage Form: Strip of 10 Tablet
 This is to inform you that the said combination is widely available and commonly marketed in Capsule dosage form and most of the approved brands are in **capsule form** due to formulation stability and pharmacological suitability. In view of the above, we request you to **kindly consider Capsule dosage form also under this tender**, in addition to Tablet form to ensure wider participation and availability of quality products.

3. Kindly consider allowing the details of authorized distributor warehouses in place of Annexure-K, or waive off the requirement of Annexure-K from the tender.

It was clarified that:-Admissible for Annual Turnover Certificate and Balance Sheet and Profit & Loss Statement only

It was clarified that :-both the Oral Dosage form of the Generic drug i.e. Capsule / Tablet is acceptable and will be treated at par, until unless explicitly not allowed by Pharmacopeia /Rules.

1. Kindly consider revising the requirement from state-wise warehouses to a four-zone-based system as described above.

2. Kindly consider restoring the delivery period to **60 days**, ensuring smoother logistics and uninterrupted supply.

3. With respect to DCGI approval for Fixed Dose Combinations (FDC), clarity is required regarding the specific documentation to be submitted.
Kindly provide detailed guidelines on documentation requirements for FDC approval to ensure compliance.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of bid submission

23. M/s Supermax drugs

1. In the case of newly launched generic versions of essential drugs, we request you to clarify if a firm meeting all Schedule M-GMP and GLP standards but having slightly less than 24 months of marketing experience for that specific drug can be considered eligible.

2. Definition of "Certified Agency": Please clarify the specific accreditation required for the certifying agency. Will certifications from NABL-accredited laboratories or ISO 17025 certified agencies be the standard requirement? Mapping Frequency: Does the MSO require a one-time validation certificate for the storage facility and transit vehicle, or must the mapping be updated periodically (e.g., annually) during the two-year Rate Contract period? Impact of Transit Delays:
In light of the current geopolitical situation in the Middle East affecting logistics, if a shipment is delayed in transit due to rerouting, will GMSD provide priority unloading for cold-chain items to ensure the integrity of the temperature-sensitive products?

3. Certain biological and antibiotic formulations naturally have a shorter shelf life (e.g., 18 months). We request the department to provide a list of exempted items or allow for products with 18 months shelf life provided they meet the 5/6th residual life at the time of delivery.

4. Given the current logistics volatility, we request extending the standard delivery period from 45 days to 60 days for the first order to allow for initial stabilization of the supply chain.

It was clarified that:-A certificate from the DCGI shall be required for all new drug formulations to this effect.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

24. M/s Medopharm

1. In view of the above, we request:
• Acceptance of a zonal warehouse system (minimum 4 depots) in Zone, in line with practices followed in Employees' State Insurance Corporation (ESIC) tenders.
• Acceptance of the following documents:
1. GST Registration Certificate
2. Drug License of Warehouse
(ESIC tender clause enclosed for your kind reference.)

2. Please note that, state drug controller can only issue drug license of Fix dose combination (FDC) subject to provide by DCGI, Hence request to kindly list of FDC drug approved by DCGI which is available on their official portal and in the public portal As ESIC is also accepting same (tender clause enclosed for your reference,

3. Due to America -Iran War situation acute shortage of Api and disrupted whole supply chain however we request to kindly increased delivery period 60 days instead of 45 days

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of supply of drugs.

Not admissible

25. M/s FDC Ltd

1. we have operational warehouse in Zirakpur which cover our entire haryana location. So please consider the same for tender requirement.

It is clarified that:- Karnal is located in Haryana and Zirakpur is in Punjab; however, both fall within close proximity and share Chandigarh as the common capital region. Considering the operational feasibility and proximity, bidders may be allowed to supply drugs to the Karnal depot from their Zirakpur Warehouse.

2. Amendment in the Packing & Specification of the below drugs:

Drug Code	Name of the Item with Specification	Preferable Pack Size	Our offered Packing/Specification	Remarks/Justification
G210080	Flurbiprofen 0.03% w/v Eye Drop	5 ML	Now we changed the packsize form 5ML to 10 ML	As per our pack 10 MLs, kindly allow this change.

It was clarified that:-The bigger pack size than the as per Schedule of requirement will be acceptable but the rate quoted will at par with the rates offered for the pack size as mentioned in the schedule

VMS No.	Item Name as per tender	Request for tender
020040	Diacerein 50mg Tab	As per current tender list these products are required in strip of 10 tab and in this regard we would like to inform you that most of the companies are making this product in strip of 15 tab packing because of its dose regimen, So requesting you to approve both the pack size's (15 tab per strip and 10 tab per strip) this will enhance the number of bidder and you will get the most competitive price for the same.
G060365	Itraconazole 200mg	
G170074	Domperidone 30mg + Esomeprazole 20mg Tab	
G170078	Domperidone 30mg + Rabeprazole 20mg Tab	
G170098	Esomeprazole 40mg + Levosulpiride 75mg Tab	
G170196	Oxetacaine 10mg+Sucralfate 1000mg	
G270048	Calcitriol 0.25 mcg + Elemental Calcium 200 mg	
G180443	Levothyroxine 25mcg Tab	As per current tender product list mentioned product name Levothyroxine 25 is required in strip of 10 tab and in this regard we would like to inform you that Levothyroxine and thyroxine is same molecule and most of companies are making this product with the name of thyroxine in pack size of 120 tab per bottle packing because of its dose regimen, So requesting you to approve both the name and pack size's (thyroxine or Levothyroxine in a pack size of 120 tab per bottle and 10 tab per strip) this will enhance the number of bidder and you will get the most competitive price for the same.

It is clarified that :
Strip 15 tablets shall be acceptable to the condition that other terms & condition of packing / pack size of the bid document are adhering.

It is clarified that :
Bottle of 120 tablets shall be acceptable to the condition that other terms & condition of packing / pack size of the bid document are adhering and name remain as per schedule of recruitment.

27. M/s Concept Pharmaceutical

- 1. Clause on Warehouse in Every Center**
The requirement to maintain a warehouse at each GMSD center.

Request: Allow a centralized warehousing model with defined delivery timelines instead of mandatory presence at every center.
- 2. Shelf-Life (75% Rule)**
Request: Deduct PDI/testing time from shelf-life requirement.
- 3. Barcoding Requirement**
Request: Allow Tier-1/2 or sticker-based coding for this tender cycle.
- 4. Force Majeure / API Shortage**
Request: Include a "Supply Chain Disruption" clause.

It was clarified that:-As this is a part of our approved tender document and cannot be changed.

	<p>1. DCGI Permission for all FDC and new Drug quoted (if applicable): As the DCGI issues the Permission for any FDC for the 1st time, and after 4 years all the regional FDA's issues Permission to any Pharma Company. So once DCGI issues Permission for any FDC then there is no need to take permission from DCGI for every pharma company.</p> <p>2. Regarding Annexure-J: Undertaking regarding Batch Manufacturing Record & API Linkage Form along with each and every supply is not feasible. One time during Technical Bid Submission in Tender documentation is possible but for every supply will create additional burden of documentation along with supplies.</p> <p>3. Our concern is that maintaining warehouses across all seven GMSD Depot locations poses significant operational and financial challenges for pharmaceutical companies. In view of the above, we would like to propose a practical alternative for your consideration. Instead of mandating warehouses in each GMSD Depot location, the country may be divided into four operational zones, with the requirement for bidders to maintain at least one warehouse in each zone.</p> <p>4. Undertaking to provide STP along with supplies: STP is provided one time for testing the product. And every time with supplies will create additional burden documentation.</p>	<p>It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of supply of drugs.</p> <p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p> <p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p> <p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p>
<p>29. M/s East African (India) Overseas</p>	<p>we would like to bring to your notice a newly introduced clause in the tender requiring every tenderer to maintain seven warehouses across seven depots in the state. We respectfully submit that this condition is not feasible for us, as we are a manufacturer and have been successfully supplying without such a requirement in the past. Therefore, we humbly request you to kindly consider amending this clause or applying it only to new participants or first-time manufacturers in the tender process.</p>	<p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p>
<p>30. M/s Zenith Drugs Ltd.</p>	<ol style="list-style-type: none"> 1. Deduct the period of PDI/Testing from the mandatory shelf-life calculation. 2. Allow Tier-1/2 for primary packaging and sticker-coding for urgent emergency supplies. 3. We suggest that the GMSD should allow a "Centralized Warehouse" instead of a mandatory physical presence in every center. This meets their goal of availability without the unnecessary infrastructure waste. 4. Include a clause for "Supply Chain Disruption" beyond the manufacturer's control. 	<p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p> <p>Not Admissible</p>
<p>31. M/s Vivimed Lab Ltd</p>	<ol style="list-style-type: none"> 1. Kindly consider revising the requirement from state-wise warehouses to a four-zone-based system as described above. 2. Kindly consider restoring the delivery period to 60 days, ensuring smoother logistics and uninterrupted supply. 3. Kindly provide detailed guidelines on documentation requirements for FDC approval to ensure compliance. 	<p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p> <p>It is clarified that :-the delivery period of 45 days is as per the approved tender conditions and cannot be increased</p> <p>It was clarified that:-CDSCO approval/certificate for FDC Fixed Dose Combination Drugs may be furnished by the bidder at the time of supply of drugs.</p>
<p>32. M/s Maxmed Life science Pvt Ltd</p>	<ol style="list-style-type: none"> 1. Clause regarding multi-state Warehouse / Drug License / GST Registration: We would like to respectfully submit that, after the implementation of GST, the necessity of maintaining multiple state-wise GST registrations and offices has largely been eliminated. 2. Revision in Turnover Criteria: The turnover requirement has been increased from ₹50 crores to ₹100 crores and from ₹100 crores to ₹200 crores for respective groups of medicines. This revision restricts companies like ours, despite having an average turnover exceeding ₹150 crores over the past three years, from participating in certain categories. 	<p>It was clarified that:-As this is a part of our approved tender document and cannot be changed.</p>


SI No.	Item Description (Nomenclature + Strength + Specification)	VMS No	Packing/Pack Size/Dosage Form	Desired Amendment / Clarification	
186	Budesonide 200mcg + Formoterol Fumarate 6mcg Rotacap	G250065	Rotacaps	Need clarity on rate to be quoted on unit /Pack of 30	<p>It was clarified that:-Rates shall benormalized appropriately on a per unit basis .</p> <p>It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.</p> <p>It was clarified that :-the Strength/composition mentioned in the Schedule of Requirement must be strictly adhered to by the bidder and Rates shall be normalized appropriately on a per unit basis .</p> <p>It was clarified that:-Alternative pack sizesmay be considered provided all other tender conditions are complied with. Rates shall be normalized appropriately on a per unit basis wherever required.</p> <p>It was clarified that:- Alternative pack sizes may be considered provided all other tender conditions are complied with. Rates shall be normalized appropriately on a per unit basis wherever required.</p> <p>It was clarified that:-Packing/Pack Size/Dosage Formmentioned in the Schedule of Requirement must be strictly adhered to by the bidder</p> <p>It was clarified that:- The pack size in the schedule of requirement is as per the prevalent pack size preferred by our user department and as per past practice and cannot be amended.</p> <p>It was clarified that:- Rates shall be normalized appropriately on a per unit basis .</p> <p>It was clarified that :-the Packing/PackSize/DosageForm mentioned in the Schedule of Requirement must be strictly adhered to by the bidder.</p>
187	Budesonide 400mcg + Formoterol Fumarate 12mcg Disk	G250070	Disk	1. Request to change disk to dry powder inhaler of 60 doses. 2. Request to accept FORMOTEROL FUMARATE 6 MCG + BUDESONIDE 400 MCG as only available with dry powder Inhaler.	
188	Budesonide 400mcg+ Formoterol Fumarate 6mcg Resicap	G250073	Resicap	1. Need to accept respicap /rotacap. 2. Need clarity on rate to be quoted on unit/ Pack of 30.	
197	Fluticasone 100mcg +Umeclidinium 62.5mcg + Vilanterol 25mcg Inhaler	G250150	30 Dose Inhaler	1. Request to ammend 30- 60 dose inhaler in packing as Cipla will quote make in India product as other brand is imported. 2. request to consider rates per dose.	
207	Ipratropium 40mcg Rotacap	G250210	Strip of 10 Capsule	1. Request to consider pack of 30 Capsule. 2. request rate to be quoted per unit /capsule.	
206	Indacaterol Maleate 110mcg + Glycopyrronium Bromide 50mcg Kit (Inhaler + Cap)	G250200	Box of 30 caps with 1 Inh	Request to accept 1 box of 30 Caps+ 1 Inh instead of single kit as already same accepted in Defence Rate contract (attached for reference).	
199	Fluticasone 250mcg + Salmeterol 50mcg Inhaler	G250155	120 MD Inhaler	1. As requested, combination is available only in dry powder inhaler, requesting to accept 60 doses dry powder Inhaler.	
200	Fluticasone 250mcg+ Salmeterol 50mcg Rotacap	G250161	Disk	Need clarity on rate to be quoted on unit/pack of 30.	
201	Fluticasone 500mcg+ Salmeterol 50mcg Disk	G250150	30 Dose Inhaler	Request to change disk to dry powder inhaler of 60 doses.	

on to above, the following queries were raised by the prospective bidder/s in the Pre-Bid meeting and clarification was given by the Committee.

Sl. No.	Query Raised	Clarification
1	The representative from M/s Quickmed Pharmaceuticals Raised the query with respect to	
a	Non conviction certificate regarding	It was clarified that Non conviction certificate either have the tender id of this tender or in general without specifying any tender ID.
b	Tender ID In annual turnover certificate and Balance sheet and profit and loss statement regarding	It was clarified that Annual turnover and balance sheet certificate without tender IDS acceptable
c	Scanned copy of original labels of quoted drugs	It was clarified that The bidder has to submit sample of the primary packing to the GMSD Before tender opening
d	Manufacturing and Marketing certificate regarding	It was clarified that Third party is not admissible
e	Copy of DCGI permission for FDC	It was clarified that DCGI permission certificate to be submitted
2	The representative from M/s Wings biotech Raised the query with respect to	
a	Item description for Lactulose 3.335 GM syrup VMS number G 170129 Regarding	It was clarified that Item Description Lactulose 3.335g each 5ML (It will be issued as corrigendum to the bid document)
b	Undertaking regarding Batch manufacturing record and API linkage form Annexure J for imported products	It was clarified that The relaxation has been granted for imported products
3	The representative from M/s Bharat Pharmaceuticals Raised the query with respect to	
a	Annexure K warehouse regarding (To supply medicines to Delhi and Karnal GMSD from Gurgaon warehouse)	Admissible
b	Copy of DCGI permission for FDC	It was clarified that DCGI permission certificate to be submitted
4	The representative from M/s Lupin Pharmaceuticals Raised the query with respect to	
a	Offered dosage form is chewable	It was clarified that Added value low to high is acceptable
5	The representative from M/s Naprood Life Sciences Raised the query with respect to	
	Annexure K Warehouse regarding (Require time to establish three more warehouse)	Admissible subject to submission of proof of application for new drug license for new Warehouse , proof of application for GST registration at the time of bid submission. Relaxation granted for 3 months GST return, only in case of newly established warehouse. Also the bidder has to submit issued certificates till 25-05-2026 before finalisation of Technical Evaluation.
6	The representative from M/s JPEE Drugs Raised the query with respect to	
a	Annexure K warehouse regarding	It was clarified that it is part of our approved tender document and cannot be changed
b	Annual turnover group A and group B regarding	It was clarified that it is part of our approved tender document and cannot be changed
c	Already registered Manufacturing firms regarding	It was clarified that The firms may supply medicines till they have active RCs
d	Stamping of stocks to be issued to GMSD	It was clarified that The road map has already been Conveyed and uploaded on the DVDMS portal


These minutes, including all clarifications issued herein, shall form an integral part of the tender document. **No further queries shall be entertained after issuance of these minutes.**


The meeting concluded with a vote of thanks to the Chair.



Shalini
PCC, GMSD New Delhi



Aniket Tangri
PCC, GMSD New Delhi


Chohan Tudu
ADM, GMSD New Delhi


Girdhari Lal
Sr. Accounts Officer, GMSD, New Delhi












Dr. G.S. Jhankar
CMO (NFSG) In-charge GMSD, New Delhi


Dr. Zeesaly S K Marak
AD, MSD (CGHS), Gole Market New Delhi


Dr. Anju Nanda
DDG (Stores) MSO
(Chairperson)














ATTENDANCE SHEET

The following representative/s of the firm/s attended the Pre-bid meeting held on 10.04.2026 at 11.00 Hours at Govt. Medical Store Depot, C-4 Qutab Institutional Area New Delhi-110016 against Tender Number: PS/2/RE/Gr B/249/2026-2027/01 (Tender ID No. 2026_DGHS_904224) for Supply of 249 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Firm and Address	Name of the Representative	Contact No./Mobile no.	E-mail id for communication	Signature
1	Zim LABORATORIES Ltd. - Mayapur	Manish Mishra +1	9911130378	manish.mishra@zimlab.in	
2	Conservation Pharma Limited Lucknow	Sumit Kumar	9045590871	sumit.kumar@conservationpharma.com	
3	Amgen Drug Dr. Arunk. Sachin Rakesh Joshi	Dr. Arunk. Sachin Rakesh Joshi	9873539595	Rakesh Joshi @ Anubhmed.com	
4	Anubhava Mehiquife	Vijay Madan	9873160232	vijay.madan@anubhmed.com	
5	^{EAST Africa} Sachin Jain ^{India} ^{overseas}	Sachin Jain	9873469990	tender@eastindia.com	
6	Deepak Mathur Dr. Reddy's Lab Ltd.	Deepak Mathur	9312142145	Deepakmathur@Dr.Reddys.com	
7	Prices Chemipharma	Santosh Jai	980981835	379.0278@jainl.com	
8	Naprod Life	Saunyanan	9968071118	Ranjan Kumar.. Binul @ naprodgroup.com	
9	Tablet India Ltd	Jai Kumar	8054193044	hd@tabletindia.com	
10	Deepak Mathur Bharat Paswan	Ontkar Nath Yadav	9958319558	ontkary3@gmail.com	

ATTENDANCE SHEET

The following representative/s of the firm/s attended the Pre-bid meeting held on 10.04.2026 at 11.00 Hours at Govt. Medical Store Depot, C-4 Qutab Institutional Area New Delhi-110016 against Tender Number: PS/2/RE/Gr B/249/2026-2027/01 (Tender ID No. 2026_DGHS_904224) for Supply of 249 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Firm and Address	Name of the Representative	Contact No./Mobile no.	E-mail id for communication	Signature
11	Sr. Srinivas Rao VIVIMED LABS Hyd.	Sr. Srinivas Rao	9849804590	Sivalanka.v@ vivimedlabs.com	
12	Samarth Life Sciences Mumbai	VIKAS PACHORI + Ra Dindar	7011450223	rajm68@ gmail.com	
13	V. Bhaskar Rao Concord Laboratories M-1	V. Bhaskar Rao	9566004588	concordlab.com	
14	A.G. PRASAD DWD pharmaceuticals at CMB AT.	A.G. PRASAD	9820852977	agprasad365@gmail.com	
15	Ankit Gupta Excel Life care Pharm	Ankit Gupta	9123643412	excelmedica807@gmail.com	
16	Tanya Jain Quickmed	Tanya Jain	882642877	quikmedhealthmetrocare @gmail.com	
17	Tanya Jain Quickmed	Tanya Jain	971125248	info.vivimedlabs @gmail.com	
18	MASAT Health Services MADAD. KROHM	Monaoy. Krohm	9871594946	masat.skm-19636 jale.in	
19	LUPIN LTD	Hemant Sethi	9810054371	hemant.sethi @lupin.com	
20	Bal pharmaceuticals ARISUN PHARM	Rajesh Singh	9480811168		
21	ARISUN PHARM	Vinod Kumar	921101142		











ATTENDANCE SHEET

The following representative/s of the firm/s attended the Pre-bid meeting held on 10.04.2026 at 11.00 Hours at Govt. Medical Store Depot, C-4 Qutab Institutional Area New Delhi-110016 against Tender Number: PS/2/RE/Gr B/249/2026-2027/01 (Tender ID No. 2026_DGHS_904224) for Supply of 249 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Firm and Address	Name of the Representative	Contact No./Mobile no.	E-mail id for communication	Signature
21	KAPIL JAGGA ALCON, Bangalore	KAPIL JAGGA	9015749717	Kapiljagga@alcon.com	Kapil J
22	PANKAJ KUMAR SINHA Lilly	PANKAJ KUMAR INDERAZ SINHA	957221116	pankaj.sinha@lilly.com	K
23	Apoorva Chatur Mankind Pharma	Apoorva Sharma H	9910919989	apoorva.sharma@mankindpharm.com	Apoorva
24	Macleods Pharmaceuticals Ltd.	VIPIN KUMAR	9250020301	vipin@macleodspharma.com	Vipin
25	Sajeev Bajaj Bayer		9810886496	sajeev.bajaj@bayer.com	Sajeev
26	MAHAGAR	SU LAD	987159494	Mahendra dash @ bsv.in	Mahendra
27	R. N. Jha	Brown lab Ch	9800275984	inst@brownlab.in	R
28	Shiv Torrent Pharm	Shiv	9716355326	shivkumar.kostari@torrent.com	Shiv
29	Shiv +1	Jeep Duesen	9800996109		Shiv
30	Amr + P. Keerav	Mazmed P. S. Phew	9999728308 9311083082	amr@mazmedpharm.com	Amr

ATTENDANCE SHEET

The following representative/s of the firm/s attended the Pre-bid meeting held on 10.04.2026 at 11.00 Hours at Govt. Medical Store Depot, C-4 Qutab Institutional Area New Delhi-110016 against Tender Number: PS/2/RE/Gr B/249/2026-2027/01 (Tender ID No. 2026_DGHS_904224) for Supply of 249 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Firm and Address	Name of the Representative	Contact No./Mobile no.	E-mail id for communication	Signature
31	keeford Healthcare	Somnath Mishra	9355600955	Somnath@keeford.in	
32	Cadila Pharma	Kapil Dutt Sandeep Kaul	8285035825	Kapil.dutt@cadila.com	
33	Wings Biotech LLP	Sandeep Kathuria	9871112871	manoj.patel@wingsbiotech.com	
34	windas biotech	Noumit + Maider	9560442329	intionca@windasbiotech.com	
35	Intra Pharma	Palash Dalta	9910065011	Palash.dalta@intrapharma.com	
36	CIPRA LTD	Kaushal Singh	874297765	Kaushal.singh@cipra.com	
37	Med Manor Organics	Y.P. Mishra	9310222501	Yogendra.Mishra@medmanor.in	
38	Subodh Karsan FDC Ltd	Subodh Karsan	999900524	Subodh.Karsan@fdcltd.com	
39	Refresh Drugs	Cipran Singh	9971949911	Cipran.Singh@RefreshDrugs.com	
40	Jitsan Ltd AJAY GANDHI	ERIS ZEON LIFE S.	9820507013 9010577789	Jitendra.Jadhav@jitsan.com msm.dutta@zeon.com	

(41)	salud cme	Sasin	9716889440	Sasinok huda, 1020	2
	Zyplus	Rajeev	93100538780	7 net. com	
(42)	Zyplus			Rajeev kumar . 8307a	
(43)	RPG LifeSctd	Vijay	7428401144	vijay.kumar@gmail.com	OK
				@ rpg/s.com	